hikma

Hikma delivers a resilient underlying performance in 2022

Hikma delivers a resilient underlying performance in 2022

23 February، 2023

Amman, Jordan — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today...

Read More

Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region

Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region

3 January، 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new...

Read More

Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region

Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region

27 December، 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces...

Read More

Hikma and Celltrion Healthcare sign exclusive licensing agreement for ustekinumab for the Middle East and North Africa region

Hikma and Celltrion Healthcare sign exclusive licensing agreement for ustekinumab for the Middle East and North Africa region

30 November، 2022

London, England — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive...

Read More

Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded

Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded

3 November، 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today...

Read More

Hikma and Adalvo Sign Exclusive Licensing Agreement to Commercialise Allergic Rhinitis Medication across MENA Markets

Hikma and Adalvo Sign Exclusive Licensing Agreement to Commercialise Allergic Rhinitis Medication across MENA Markets

25 August، 2022

Amman, Jordan — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive...

Read More

Hikma’s diversified business delivers resilient H1 performance

Hikma’s diversified business delivers resilient H1 performance

4 August، 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company,...

Read More

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

18 July، 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an...

Read More

Siggi Olafsson to step down as Chief Executive

Siggi Olafsson to step down as Chief Executive

24 May، 2022

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma) today announces that Siggi Olafsson has...

Read More

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

29 April، 2022

London, England – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides...

Read More